Driehaus Capital Management’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Driehaus Capital Management’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-44,016	Closed	-$653K	–	542
2018 Q3	$653K	Sell	44,016 -26,115	-37%	-$411K	0.02%	387
2018 Q2	$1.18M	Sell	70,131 -29,869	-30%	-$580K	0.04%	328
2018 Q1	$2.29M	Hold	100,000	–	–	0.08%	241
2017 Q4	$2.59M	Sell	100,000 -162,569	-62%	-$3.27M	0.1%	236
2017 Q3	$3.87M	Sell	262,569 -225,716	-46%	-$3.28M	0.15%	183
2017 Q2	$6.81M	Buy	488,285 +57,303	+13%	+$845K	0.25%	91
2017 Q1	$7.35M	Buy	+430,982	New	+$5.17M	0.25%	89

Other funds holding CNCE

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Driehaus Capital Management's CNCE Position: Q4 2018 in Review

Driehaus Capital Management sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q4 2018, closing a stake of 44,016 shares — an estimated $653K sold.

Driehaus Capital Management first reported a position in CNCE in Q1 2017 and held it in 7 quarters. The position peaked at $7.35M in Q1 2017. 93 funds tracked by Wall St. Rank hold CNCE as of Q4 2018.

Driehaus Capital Management reported no remaining Concert Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
Driehaus Capital Management sold 44,016 Concert Pharmaceuticals, Inc. shares in Q4 2018, an estimated $653K.
Driehaus Capital Management first reported a position in Concert Pharmaceuticals, Inc. in Q1 2017 and held it in 7 quarters.
Driehaus Capital Management's Concert Pharmaceuticals, Inc. position peaked at $7.35M in Q1 2017.
93 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q4 2018.

Based on Driehaus Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.